OneLife SA

Key People

• Kristof Nijs - CEO
• Martine Weickmans - COO
• Victoria Blackman - CFO
• David Limme - Marketing Manager
• Astrid Nemegeer - Product Manager
• Stphanie Vermeiren - Production & Quality Manager
• Marjorie Place - Business Development Manager & Healthcare Advisor
• Danil Wouters - Business Development Manager
• Caroline Adriaens - International Business Development Manager
• Pierre Haze - International Business Development Manager
• Laetitia Fontaine - R&D Projects Manager
• Lucie Cariaux - R&D Formulator
• Thi My-Dung Tran - HR Manager
• Isabelle Mostin - Back Office

Assessment

Team

Aspect: First-time 10+ yrs
Summary: The leadership team comprises individuals with over a decade of experience in their respective fields, though specific MedTech entrepreneurial success is not highlighted.

While the team members have significant experience in their roles, the absence of demonstrated success in MedTech startups may pose challenges in navigating the industry's unique demands.

Clinical Need

Aspect: Very Strong
Summary: The company's focus on decontamination solutions addresses a critical need in healthcare to prevent infections and combat antimicrobial resistance.

With biofilms responsible for 65% of all infections and increasing antimicrobial resistance, effective decontamination solutions are essential in healthcare settings.

Competition

Aspect: Somewhat crowded
Summary: The bio decontamination market has multiple players, but opportunities exist for differentiation through innovative enzymatic solutions.

While the market is competitive, OneLife's patented enzymatic technology offers a unique approach to biofilm removal, potentially setting it apart from traditional chemical-based solutions.

Technical Challenge

Aspect: Moderate
Summary: Developing effective enzymatic decontamination solutions involves moderate technical challenges, including enzyme stabilization and efficacy across various biofilms.

Ensuring that enzymatic detergents effectively break down diverse biofilm matrices without compromising safety or material integrity involves complex formulation and testing processes.

Patent

Aspect: Very Strong
Summary: OneLife holds patents for its enzymatic decontamination technology, providing a strong intellectual property position.

Patents such as EP2789682A1 and EP2243821 cover OneLife's enzymatic solutions, offering protection against competitors and potential licensing opportunities.

Financing

Aspect: Medium
Summary: The company has secured funding from multiple investors, indicating moderate financial backing.

While investments from entities like Merlion Group and Noshaq provide financial support, additional funding may be necessary to fully capitalize on market opportunities and expand operations.

Regulatory

Aspect: 510k/PMA
Summary: The company's products likely require regulatory approvals such as 510(k) or PMA, which are standard but time-consuming processes.

Obtaining necessary regulatory clearances is crucial for product commercialization, and the associated timelines and requirements can impact the company's go-to-market strategy.

Opportunity Rollup

Odds of Success

3.6

Peak Market Share

5.15

Segment CAGR

7.0%

Market Segment

Bio Decontamination

Market Sub Segment

Enzymatic Cleaning Solutions

Key Takeaway

OneLife SA's innovative enzymatic decontamination solutions address a critical need in infection control, supported by strong patents and a growing market, though challenges in competition and financing remain.